BiomX Inc
For the period ended Dec 31, 2023. Filed Apr 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 4, 2024
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common stock · Additional paid in · Accumulated · Total Stockholder’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | capital | deficit | equity | |
| Balance as of December 31, 2021 | 29,747,538 | 2 | 156,017 | (108,484) | 47,535 |
| Issuance of Common Stock under Open Market Sales Agreement net of $8 issuance costs (**) | 229,044 | * | 273 | - | 273 |
| Stock-based compensation expenses | - | - | 1,529 | - | 1,529 |
| Proceeds on account of shares (***) | - | - | 19 | - | 19 |
| Net loss | - | - | - | (28,317) | (28,317) |
| Balance as of December 31, 2022 | 29,976,582 | 2 | 157,838 | (136,801) | 21,039 |
| Issuance of Common Stock and warrants under Private Investment in Public Equity (“PIPE”), net of $333 issuance costs (**) | 15,997,448 | 1 | 7,151 | - | 7,152 |
| Reissuance of treasury stock (***) | 5,700 | - | - | - | - |
| Stock-based compensation expenses | - | - | 1,059 | - | 1,059 |
| Issuance of Common Stock under Open Market Sales Agreement (**) | 200 | * | * | - | * |
| Net loss | - | - | - | (26,169) | (26,169) |
| Balance as of December 31, 2023 | 45,979,930 | 3 | 166,048 | (162,970) | 3,081 |
| (*) | Less than $1. |
|---|
| (**) | See note 12A. |
|---|---|
| (***) | See note 9A. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.